Related Experiment Videos
Thyrotropin serum concentrations in patients with papillary thyroid microcancers
Marion Gerschpacher1, Christian Göbl, Christian Anderwald
1Department of Internal Medicine III, Medical University of Vienna , Vienna, Austria .
Summary
Thyroid-stimulating hormone (TSH) levels were similar in patients with papillary thyroid microcarcinoma (PTMC) and controls. This suggests TSH may not initiate, but could influence the growth of, small thyroid cancers.
Area of Science:
- Endocrinology
- Oncology
- Thyroid Research
Background:
- Elevated serum thyrotropin (thyroid-stimulating hormone [TSH]) is linked to increased differentiated thyroid cancer risk.
- TSH measurement may aid in assessing cancer risk for small thyroid nodules.
- This study investigates TSH levels in papillary thyroid microcarcinoma (PTMC).
Purpose of the Study:
- To compare preoperative serum TSH concentrations in PTMC patients versus a control group.
- To evaluate the role of TSH in the development of small differentiated thyroid cancers.
Main Methods:
- Retrospective cross-sectional analysis of 33 PTMC patients and 54 controls.
- Controls had medullary thyroid carcinoma or c-cell hyperplasia without thyroid cancer.
- Exclusion criteria included thyroid-affecting medications and prior thyroid surgery/cancer.
Main Results:
- Mean TSH levels were comparable between PTMC patients (1.40 mLU/L) and controls (1.43 mLU/L).
- No significant difference in TSH was observed between the groups (p = 0.912).
- A trend suggested a positive correlation between nodule size and TSH in PTMC patients (p = 0.066).
Conclusions:
- TSH is not elevated in PTMC patients, suggesting it's not involved in de novo oncogenesis.
- TSH may play a role in the progression of existing PTMCs rather than their initiation.
